172 related articles for article (PubMed ID: 37129853)
1. Gold Nanoparticles Inhibit Macropinocytosis by Decreasing KRAS Activation.
Elechalawar CK; Rao G; Gulla SK; Patel MM; Frickenstein A; Means N; Roy RV; Tsiokas L; Asfa S; Panja P; Rao C; Wilhelm S; Bhattacharya R; Mukherjee P
ACS Nano; 2023 May; 17(10):9326-9337. PubMed ID: 37129853
[TBL] [Abstract][Full Text] [Related]
2. Ubiquitin-binding associated protein 2 regulates KRAS activation and macropinocytosis in pancreatic cancer.
Xiong X; Rao G; Roy RV; Zhang Y; Means N; Dey A; Tsaliki M; Saha S; Bhattacharyya S; Dhar Dwivedi SK; Rao CV; McCormick DJ; Dhanasekaran D; Ding K; Gillies E; Zhang M; Yang D; Bhattacharya R; Mukherjee P
FASEB J; 2020 Sep; 34(9):12024-12039. PubMed ID: 32692445
[TBL] [Abstract][Full Text] [Related]
3. Phellodendrine chloride suppresses proliferation of KRAS mutated pancreatic cancer cells through inhibition of nutrients uptake via macropinocytosis.
Thu PM; Zheng ZG; Zhou YP; Wang YY; Zhang X; Jing D; Cheng HM; Li J; Li P; Xu X
Eur J Pharmacol; 2019 May; 850():23-34. PubMed ID: 30716311
[TBL] [Abstract][Full Text] [Related]
4. Atypical KRAS
Hobbs GA; Baker NM; Miermont AM; Thurman RD; Pierobon M; Tran TH; Anderson AO; Waters AM; Diehl JN; Papke B; Hodge RG; Klomp JE; Goodwin CM; DeLiberty JM; Wang J; Ng RWS; Gautam P; Bryant KL; Esposito D; Campbell SL; Petricoin EF; Simanshu DK; Aguirre AJ; Wolpin BM; Wennerberg K; Rudloff U; Cox AD; Der CJ
Cancer Discov; 2020 Jan; 10(1):104-123. PubMed ID: 31649109
[TBL] [Abstract][Full Text] [Related]
5. Intracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosis.
Liu X; Ghosh D
Int J Nanomedicine; 2019; 14():6589-6600. PubMed ID: 31496700
[TBL] [Abstract][Full Text] [Related]
6. Exploiting macropinocytosis for drug delivery into KRAS mutant cancer.
Liu H; Qian F
Theranostics; 2022; 12(3):1321-1332. PubMed ID: 35154489
[TBL] [Abstract][Full Text] [Related]
7. KRAS
Hobbs GA; Der CJ
Subcell Biochem; 2022; 98():205-221. PubMed ID: 35378710
[TBL] [Abstract][Full Text] [Related]
8. A recombinantly tailored β-defensin that displays intensive macropinocytosis-mediated uptake exerting potent efficacy against K-Ras mutant pancreatic cancer.
Du Y; Shang BY; Sheng WJ; Zhang SH; Li Y; Miao QF; Zhen YS
Oncotarget; 2016 Sep; 7(36):58418-58434. PubMed ID: 27517152
[TBL] [Abstract][Full Text] [Related]
9. Dual blockade of macropinocytosis and asparagine bioavailability shows synergistic anti-tumor effects on KRAS-mutant colorectal cancer.
Hanada K; Kawada K; Nishikawa G; Toda K; Maekawa H; Nishikawa Y; Masui H; Hirata W; Okamoto M; Kiyasu Y; Honma S; Ogawa R; Mizuno R; Itatani Y; Miyoshi H; Sasazuki T; Shirasawa S; Taketo MM; Obama K; Sakai Y
Cancer Lett; 2021 Dec; 522():129-141. PubMed ID: 34543685
[TBL] [Abstract][Full Text] [Related]
10. Anticipating resistance to KRAS inhibition: a novel role for USP21 in macropinocytosis regulation.
Crawford HC
Genes Dev; 2021 Oct; 35(19-20):1325-1326. PubMed ID: 34599002
[TBL] [Abstract][Full Text] [Related]
11. CX-4945 (Silmitasertib) Induces Cell Death by Impairing Lysosomal Utilization in
Lee DS; Han MW; Kang Y; Kim C; Lee S; Kim KP; Yoo C
Anticancer Res; 2024 May; 44(5):1939-1946. PubMed ID: 38677763
[TBL] [Abstract][Full Text] [Related]
12. KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated drugs.
Liu H; Sun M; Liu Z; Kong C; Kong W; Ye J; Gong J; Huang DCS; Qian F
J Control Release; 2019 Feb; 296():40-53. PubMed ID: 30653981
[TBL] [Abstract][Full Text] [Related]
13. Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer.
Yao W; Rose JL; Wang W; Seth S; Jiang H; Taguchi A; Liu J; Yan L; Kapoor A; Hou P; Chen Z; Wang Q; Nezi L; Xu Z; Yao J; Hu B; Pettazzoni PF; Ho IL; Feng N; Ramamoorthy V; Jiang S; Deng P; Ma GJ; Den P; Tan Z; Zhang SX; Wang H; Wang YA; Deem AK; Fleming JB; Carugo A; Heffernan TP; Maitra A; Viale A; Ying H; Hanash S; DePinho RA; Draetta GF
Nature; 2019 Apr; 568(7752):410-414. PubMed ID: 30918400
[TBL] [Abstract][Full Text] [Related]
14. Macropinocytosis Renders a Subset of Pancreatic Tumor Cells Resistant to mTOR Inhibition.
Michalopoulou E; Auciello FR; Bulusu V; Strachan D; Campbell AD; Tait-Mulder J; Karim SA; Morton JP; Sansom OJ; Kamphorst JJ
Cell Rep; 2020 Feb; 30(8):2729-2742.e4. PubMed ID: 32101748
[TBL] [Abstract][Full Text] [Related]
15. KRAS: feeding pancreatic cancer proliferation.
Bryant KL; Mancias JD; Kimmelman AC; Der CJ
Trends Biochem Sci; 2014 Feb; 39(2):91-100. PubMed ID: 24388967
[TBL] [Abstract][Full Text] [Related]
16. Eicosapentaenoic Acid Inhibits
Chiu CF; Hsu MI; Yeh HY; Park JM; Shen YS; Tung TH; Huang JJ; Wu HT; Huang SY
Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33801246
[TBL] [Abstract][Full Text] [Related]
17. KRAS Addiction Promotes Cancer Cell Adaptation in Harsh Microenvironment Through Macropinocytosis.
Seguin L
Subcell Biochem; 2022; 98():189-204. PubMed ID: 35378709
[TBL] [Abstract][Full Text] [Related]
18. A Macropinocytosis-Intensifying Albumin Domain-Based scFv Antibody and Its Conjugate Directed against K-Ras Mutant Pancreatic Cancer.
Wang X; Sheng W; Wang Y; Li L; Li Y; Zhang S; Liu X; Chen S; Zhen Y
Mol Pharm; 2018 Jun; 15(6):2403-2412. PubMed ID: 29757658
[TBL] [Abstract][Full Text] [Related]
19. USP21 deubiquitinase elevates macropinocytosis to enable oncogenic KRAS bypass in pancreatic cancer.
Hou P; Ma X; Yang Z; Zhang Q; Wu CJ; Li J; Tan L; Yao W; Yan L; Zhou X; Kimmelman AC; Lorenzi PL; Zhang J; Jiang S; Spring D; Wang YA; DePinho RA
Genes Dev; 2021 Oct; 35(19-20):1327-1332. PubMed ID: 34531315
[TBL] [Abstract][Full Text] [Related]
20. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
